Highly purified Chondroitinase ABC for neural regeneration research launched by AMSBIO

Published on February 21, 2013 at 11:00 AM · No Comments

AMSBIO, a specialist supplier of high purity reagents for glycobiology and regenerative medicine, has announced the launch of a new, highly purified Chondroitinase ABC. This new enzyme is supplied protease-free, carrier-free and with low-endotoxin levels for use in neuroscience and regenerative medicine research.

Chondroitin Sulfate Proteoglycans (CSPGs) are involved in the inhibition of axon regeneration after various forms of damage to the Central Nervous System, including stroke or spinal cord injury. The enzyme Chondroitinase ABC purified from Proteus vulgaris, degrades these CSPGs, and has been shown to promote functional recovery and neural regeneration.

Backbone injury in x-ray

AMSBIO’s new Chondroitinase ABC is a direct replacement for the protease-free Chondroitinase ABC formerly supplied by Seikagaku Biobusiness Corporation (and available through AMSBIO), which was discontinued by the manufacturer in 2011 as part of their broader decision to pull out of the research reagents and glycobiology biochemicals business.

See http://www.amsbio.com/brochures/ChondroitinaseABC_flyer.pdf for more details on this new enzyme, including stability study and comparison with protease-free enzyme formerly available from Seikagaku Biobusiness Corporation.
For further information, including pricing and delivery please contact AMSBIO on +44-1235-828200 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Osteoarthritis may be treated with stem cell mobilization therapy